David A. Siegel Exelixis, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Exelixis, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 428,790 shares of EXEL stock, worth $16.4 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
428,790
Previous 2,285,090
81.24%
Holding current value
$16.4 Million
Previous $84.4 Million
77.6%
% of portfolio
0.04%
Previous 0.2%
Shares
32 transactions
Others Institutions Holding EXEL
# of Institutions
688Shares Held
260MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.28 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$1.05 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$614 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$606 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$436 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...